I-Mab TJD5 Phase 2 Clinical Trial Data Update Call Transcript
Good morning, everyone, and thank you for dialing in today. Yesterday, after market hours, we published a press release sharing our updated Phase II clinical data with a data cutoff date of March 29, 2022.
In today's discussion, we'll go through uliledlimab's key differentiating factors, the most updated Phase II clinical data as well as our global clinical development plan.
With that, I'll hand it over to Dr. Zhu.
Thank you, Tyler. Thank you all for joining this call, particularly with ASCO just approaching us next week.
During today's meeting, we would like to share with you the latest encouraging Phase II clinical data of our differentiated CD73 antibody uliledlimab.
In early 2022, we submitted an abstract of uliledlimab the initial Phase II data to ASCO, with the data cutoff date of December 13, 2021. Since then, we're very pleased that the data has matured significantly. Therefore, after the ASCO embargo, we would like to take
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
